Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Intervalo de año de publicación
1.
Diabetes Res Clin Pract ; 122: 38-45, 2016 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-27776251

RESUMEN

AIMS: Socioeconomic changes in Latin American countries have led to an increased prevalence of type 2 diabetes (T2D). We examined the effects of exenatide twice daily (BID) or insulin lispro, each added to insulin glargine, in Latin American patients with T2D. METHODS: This was a subgroup analysis of patients from Argentina and Mexico in the 4B study (N=114). Patients with glycated hemoglobin (HbA1c) of 7.0-10.0% (53-86mmol/mol) after 12weeks of intensive basal insulin optimization were randomized to exenatide BID or thrice-daily insulin lispro added to insulin glargine and metformin. RESULTS: After 30weeks, addition of exenatide BID or insulin lispro resulted in significant (P<0.0001) reductions in HbA1c (exenatide BID: -0.9% [-10mmol/mol]; insulin lispro: -1.2% [-13mmol/mol]). Weight was stable in the exenatide BID group (-0.1kg) and increased significantly (+3.4kg; P<0.0001) with insulin lispro. Major and minor hypoglycemia occurred less frequently (40 vs. 253 events) with exenatide BID compared with insulin lispro. Gastrointestinal adverse events of nausea, diarrhea, and vomiting occurred more frequently with exenatide BID than with insulin lispro. CONCLUSIONS: Both exenatide BID and prandial insulin lispro, each added to basal insulin glargine, were effective at reducing HbA1c in Latin American patients. Treatment with exenatide BID resulted in stable weight but more gastrointestinal adverse events. Treatment with insulin lispro resulted in weight gain and an increased risk of hypoglycemia. These findings support the addition of exenatide BID to insulin glargine as an option for Latin American patients unable to achieve glycemic control on basal insulin alone.


Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/uso terapéutico , Insulina Glargina/uso terapéutico , Insulina Lispro/uso terapéutico , Péptidos/uso terapéutico , Ponzoñas/uso terapéutico , Adulto , Anciano , Argentina , Glucemia/metabolismo , Peso Corporal/efectos de los fármacos , Diabetes Mellitus Tipo 2/sangre , Esquema de Medicación , Exenatida , Femenino , Hemoglobina Glucada/metabolismo , Humanos , Hipoglucemia/inducido químicamente , Hipoglucemiantes/efectos adversos , Insulina Glargina/efectos adversos , Insulina Lispro/efectos adversos , Masculino , Metformina/efectos adversos , Metformina/uso terapéutico , México , Persona de Mediana Edad , Péptidos/efectos adversos , Estudios Retrospectivos , Resultado del Tratamiento , Estados Unidos , Ponzoñas/efectos adversos
2.
An Bras Dermatol ; 87(6): 917-9, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-23197216

RESUMEN

Insulin, a crucial therapeutic agent for diabetes mellitus, has been rarely associated with hypersensitivity events. We present a 69-year-old type-2 diabetic patient with urticariform lesions on the sites of subcutaneous injection of insulin. The patient denied any known allergies, except for an unspecific cutaneous reaction after intramuscular penicillin administration in childhood. Prick tests revealed positive reactions to all tested human insulins and insulin analogues. Serum IgE levels were above normal range and RAST tests were positive for human, bovine and porcine insulins, as well as beta-lactams. Type 1 IgE-mediated allergy to insulin analogues demands a prompt diagnosis and represents a significant therapeutic challenge in diabetic patients.


Asunto(s)
Antibacterianos/efectos adversos , Hipersensibilidad a las Drogas/etiología , Hipoglucemiantes/efectos adversos , Inmunoglobulina E/inmunología , Insulina Lispro/efectos adversos , beta-Lactamas/efectos adversos , Anciano , Animales , Bovinos , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipersensibilidad a las Drogas/diagnóstico , Humanos , Masculino , Pruebas Cutáneas/métodos , Porcinos
3.
An. bras. dermatol ; An. bras. dermatol;87(6): 917-919, Nov.-Dec. 2012. ilus, tab
Artículo en Inglés | LILACS | ID: lil-656621

RESUMEN

Insulin, a crucial therapeutic agent for diabetes mellitus, has been rarely associated with hypersensitivity events. We present a 69-year-old type-2 diabetic patient with urticariform lesions on the sites of subcutaneous injection of insulin. The patient denied any known allergies, except for an unspecific cutaneous reaction after intramuscular penicillin administration in childhood. Prick tests revealed positive reactions to all tested human insulins and insulin analogues. Serum IgE levels were above normal range and RAST tests were positive for human, bovine and porcine insulins, as well as beta-lactams. Type 1 IgEmediated allergy to insulin analogues demands a prompt diagnosis and represents a significant therapeutic challenge in diabetic patients.


A insulina é um agente indispensável para o controlo da diabetes mellitus. Os efeitos adversos da sua administração, em particular fenómenos de hipersensibilidade, são raros. Apresentamos um doente de 69 anos, diabético do tipo 2, com episódios recorrentes de lesões urticariformes nos locais de administração subcutânea de insulina. Negava alergias medicamentosas, à excepção de reacção não especificada na infância após penicilina intramuscular. Foram realizados testes cutâneos por puntura (prick tests) com diversos tipos de insulina humana e análogos, todos com reacções positivas, associando elevação dos níveis de IgE sérica e provas RAST positivas para as insulinas humana, bovina e porcina e para os antibióticos beta-lactâmicos. A alergia a análogos de insulina exige um diagnóstico precoce, originando um desafio terapêutico importante no doente diabético.


Asunto(s)
Anciano , Animales , Bovinos , Humanos , Masculino , Antibacterianos/efectos adversos , Hipersensibilidad a las Drogas/etiología , Hipoglucemiantes/efectos adversos , Inmunoglobulina E/inmunología , Insulina Lispro/efectos adversos , beta-Lactamas/efectos adversos , /tratamiento farmacológico , Hipersensibilidad a las Drogas/diagnóstico , Porcinos , Pruebas Cutáneas/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA